US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amylyx Pharmaceuticals

5.52

0.0000

Post-market: 5.530.0100+0.18%19:15 EDT

Volume:890.30K

Turnover:4.87M

Market Cap:492.06M

PE:-1.83

High:5.55

Open:5.37

Low:5.33

Close:5.52

Loading ...

Overview Company News Filings

Press Release: Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Amylyx Pharmaceuticals Starts Dosing in Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment

MT Newswires Live

BRIEF-Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 Lucidity Trial of Avexitide in Post-Bariatric Hypoglycemia

THOMSON REUTERS

Amylyx Pharmaceuticals Inc - Lucidity Trial Recruitment Expected to Complete in 2025, With Topline Data in First Half of 2026

THOMSON REUTERS

Amylyx Pharmaceuticals Inc - Expects Cash Runway Through End of 2026

THOMSON REUTERS

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

BRIEF-Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose Lumina Trial of Amx0114 in People Living With Amyotrophic Lateral Sclerosis

THOMSON REUTERS

Amylyx Pharmaceuticals Inc: Amylyx Expects Early Cohort Data From Lumina This Year

THOMSON REUTERS

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Raised to Outperform From Neutral by Mizuho

Mizuho Upgrades Amylyx Pharmaceuticals to Outperform From Neutral, Raises Price Target to $7 From $3

MT Newswires Live

Amylyx Pharmaceuticals Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $7 From $3

THOMSON REUTERS

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

Amylyx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation

BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth

Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

BUZZ-Amylyx Pharmaceuticals falls on quarterly loss

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AMLX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AMLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AMLX\",,,,,undefined,":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":5.52,"timestamp":1749844800000,"preClose":5.52,"halted":0,"volume":890299,"hourTrading":{"tag":"盘后","latestPrice":5.53,"preClose":5.52,"latestTime":"19:15 EDT","volume":17571,"amount":96993.08,"timestamp":1749856543552},"delay":0,"floatShares":55694031,"shares":89141087,"eps":-3.016186,"marketStatus":"Market Closed","change":0,"latestTime":"06-13 16:00:00 EDT","open":5.37,"high":5.55,"low":5.325,"amount":4867310.234948,"amplitude":0.040761,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.016186,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":5.52,"dividendRate":0.000181,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":5.52,"preClose":5.52,"latestTime":"09:24 EDT","volume":2212,"amount":12192.320587999999,"timestamp":1749821080544},"postHourTrading":{"tag":"盘后","latestPrice":5.53,"preClose":5.52,"latestTime":"19:15 EDT","volume":17571,"amount":96993.08,"timestamp":1749856543552},"volumeRatio":0.9466897282071914,"impliedVol":0.2248,"impliedVolPercentile":0.04},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AMLX\",,,,,undefined,":{"symbol":"AMLX","floatShares":55694031,"roa":"-40.72%","roe":"-83.24%","lyrEps":-4.428139,"volumeRatio":0.9466897282071914,"shares":89141087,"dividePrice":0.001,"high":5.55,"amplitude":0.040761,"preClose":5.52,"low":5.325,"week52Low":1.575,"pbRate":"2.44","psRate":"-386.84","week52High":7.27,"institutionHeld":0,"latestPrice":5.52,"eps":-3.016186,"divideRate":0.000181,"volume":890299,"delay":0,"ttmEps":-3.016186,"open":5.37,"prevYearClose":3.78,"prevWeekClose":5.33,"prevMonthClose":5.15,"prevQuarterClose":3.54,"fiveDayClose":5.33,"twentyDayClose":4.52,"sixtyDayClose":3.65},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AMLX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532077618","title":"Press Release: Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532077618","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532077618?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:06","pubTimestamp":1746104760,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals, Inc.   will report its first quarter 2025 financial results on Thursday, May 8, 2025. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2532068449","title":"Amylyx Pharmaceuticals Starts Dosing in Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2532068449","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532068449?lang=en_us&edition=fundamental","pubTime":"2025-04-30 23:46","pubTimestamp":1746027963,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals  said Wednesday it has started dosing participants in its phase 3 trial for avexitide, a treatment for post-bariatric hypoglycemia, a condition where blood sugar drops too low after weight-loss surgery.The trial will study about 75 patients who had Roux-en-Y gastric bypass surgery, across 20 sites in the US to measure how well avexitide reduces moderate to severe low blood sugar events in 16 weeks, the company said.Patients will be randomly assigned to receive either a daily 90 mg dose of avexitide or a placebo, and those who finish the 16-week double-blind phase can join a 32-week open-label extension, it added.Amylyx said it expects to finish enrolling participants in 2025 and release top-line data in H1 2026.The company also said its cash reserves should last through the end of 2026.Shares of the company were up about 3% in recent trading.Price: 5.06, Change: +0.16, Percent Change: +3.27","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AMLX","BK4007","POST","BK4212"],"gpt_icon":0},{"id":"2531338970","title":"BRIEF-Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531338970","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531338970?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:16","pubTimestamp":1746011805,"startTime":"0","endTime":"0","summary":"BRIEF-Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric HypoglycemiaApril 30 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:AMYLY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA6SPBZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2531804700","title":"Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 Lucidity Trial of Avexitide in Post-Bariatric Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531804700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531804700?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA6SPBZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2531800470","title":"Amylyx Pharmaceuticals Inc - Lucidity Trial Recruitment Expected to Complete in 2025, With Topline Data in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2531800470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531800470?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA6SPBZF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2531800230","title":"Amylyx Pharmaceuticals Inc - Expects Cash Runway Through End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2531800230","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531800230?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA6SPBZF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2531335030","title":"Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531335030","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531335030?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"Amylyx expects completion of recruitment for the LUCIDITY trial in 2025, with topline data in first half of 2026. Pivotal Phase 3 LUCIDITY trial evaluating avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation and Orphan Drug Designation; FDA-agreed-upon primary outcome of reduction in hypoglycemic events. Avexitide has been previously evaluated in five post-bariatric hypoglycemia  clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant reductions in hypoglycemic events. LUCIDITY  is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in approximately 75 participants with PBH following Roux-en-Y gastric bypass  surgery, across approximately 20 U.S. sites. The U.S. Food and Drug Administration -agreed-upon primary endpoint of LUCIDITY is reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. The tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-first-participant-110000177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0128526141.USD","BK4212","PBH","LU0029874061.USD","LU2125154935.USD","POST","LU2125154778.USD","LU2360032135.SGD","BK4007","AMLX","HI","BK4161"],"gpt_icon":0},{"id":"2526435470","title":"BRIEF-Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526435470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526435470?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:01","pubTimestamp":1744196504,"startTime":"0","endTime":"0","summary":"BRIEF-Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral SclerosisApril 9 (Reuters) - Amylyx Pharmace","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2526354472","title":"Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose Lumina Trial of Amx0114 in People Living With Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526354472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526354472?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:00","pubTimestamp":1744196412,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2526354471","title":"Amylyx Pharmaceuticals Inc: Amylyx Expects Early Cohort Data From Lumina This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2526354471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526354471?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:00","pubTimestamp":1744196412,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM2AQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2526551553","title":"Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526551553","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526551553?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:00","pubTimestamp":1744196400,"startTime":"0","endTime":"0","summary":"- Amylyx expects early cohort data from LUMINA this year. \"AMX0114 targets calpain-2, which has been found to be an important contributor to axonal degeneration and studied over decades of research as a potential target for the treatment of ALS and other neurodegenerative diseases. In preclinical studies, AMX0114 showed improved neuronal survival and reductions in extracellular NfL levels across multiple disease models. We are excited to progress AMX0114 into the clinic for people with ALS as we work to advance a potential therapy for this relentlessly progressive, fatal disease,\" said Camille L. Bedrosian, MD, Chief Medical Officer at Amylyx.\"ALS is a devastating and fatal neurodegenerative disease with limited treatment options, underscoring the urgent need for new therapeutic approaches that target the underlying mechanisms driving ALS progression. AMX0114 represents a potential therapeutic approach to inhibiting one of the fundamental drivers of axonal degeneration,\" said Sabrina P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-first-participant-110000899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4561","BK4200","AMLX","ASO","BK4007"],"gpt_icon":0},{"id":"2525802498","title":"Amylyx Pharmaceuticals Raised to Outperform From Neutral by Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2525802498","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525802498?lang=en_us&edition=fundamental","pubTime":"2025-04-08 00:48","pubTimestamp":1744044480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 12:48 ET (16:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","MFG"],"gpt_icon":0},{"id":"2525015138","title":"Mizuho Upgrades Amylyx Pharmaceuticals to Outperform From Neutral, Raises Price Target to $7 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525015138","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525015138?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:29","pubTimestamp":1744021794,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals (AMLX) has an average rating of overweight and mean price target of $8.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AMLX","MFG"],"gpt_icon":0},{"id":"2525092920","title":"Amylyx Pharmaceuticals Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $7 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525092920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525092920?lang=en_us&edition=fundamental","pubTime":"2025-04-07 17:37","pubTimestamp":1744018631,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2517245951","title":"PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2517245951","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517245951?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:58","pubTimestamp":1741363080,"startTime":"0","endTime":"0","summary":"Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has granted an Orphan Drug Designation  to its lead radiotherapeutic candidate, rhenium  obisbemeda, for treating leptomeningeal metastases  in patients with lung cancer. The stock continued to gain another 51.4% in after-hours trading following the news announcement.The FDA grants ODD to support the development of medicines for rare disorders that affect fewer than 200,000 people in the United States. The ODD makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies, as well as exemptions from certain FDA application fees, including the Prescription Drug User Fee Act  charge of $4.3 million in 2025.LM is a rare cancer complication in which the primary cancer spreads to the cerebrospinal fluid and leptomeninges that cover the brain and spinal cord.In the past year, shares of Plus T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pstv-stock-skyrockets-fdas-orphan-155800501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","IE00B7SZLL34.SGD","PSTV","IE0002270589.USD","AMLX","BMRN","BK4139","BK4007","IE00B19Z3B42.SGD","BK4566","XNCR"],"gpt_icon":1},{"id":"2517991212","title":"Amylyx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517991212","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517991212?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:19","pubTimestamp":1741180740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2025 08:19 ET (13:19 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"gpt_icon":0},{"id":"2517689609","title":"Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517689609","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517689609?lang=en_us&edition=fundamental","pubTime":"2025-03-05 14:02","pubTimestamp":1741154532,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals, Inc. (AMLX) has disclosed a new risk, in the Corporate Activity and Growth category. Amylyx Pharmaceuticals, Inc. faces sig...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amylyx-pharmaceuticals-faces-challenges-in-acquisition-strategy-amid-relyvrio-discontinuation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amylyx-pharmaceuticals-faces-challenges-in-acquisition-strategy-amid-relyvrio-discontinuation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4516","STRK","BK4596","BK4600","BK4007","AMLX","BK4585","BK4595","BK4588","BK4023"],"gpt_icon":0},{"id":"2517600360","title":"BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600360","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517600360?lang=en_us&edition=fundamental","pubTime":"2025-03-05 02:46","pubTimestamp":1741114004,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealthEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN1GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","AAL","SNVD.UK","ATEC","CAPR","2NVD.UK","PEPG","EVGO","ENPH","HUT","ILMN","TNYA","FITB","DSP","NVDS","UAL","MDLZ","NVDD","STIM","NEXT","NVDY","PEP","WVE","CNX","WGRX","ULCC","WBA","OKTA","YMAB","3NVD.UK","NVDU","UNH","NVIW.SI","JBLU","AGH","SLRN","EQT"],"gpt_icon":1},{"id":"2516089436","title":"Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516089436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516089436?lang=en_us&edition=fundamental","pubTime":"2025-03-04 23:18","pubTimestamp":1741101519,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryAmylyx Pharmaceuticals Inc AMLX.OQ reported a quarterly adjusted loss of 55 cents per share for the quart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL5N3PN1U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX"],"gpt_icon":0},{"id":"2516116672","title":"BUZZ-Amylyx Pharmaceuticals falls on quarterly loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2516116672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516116672?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:37","pubTimestamp":1741099035,"startTime":"0","endTime":"0","summary":"BUZZ-Amylyx Pharmaceuticals falls on quarterly loss** Drug developer Amylyx Pharmaceuticals' AMLX.O shares fall 3.5% to $2.89** Company posts Q4 net loss of $37.5 million compared with net income of $4.7 million a year ago** AMLX closes its underwritten public offering of 19.7 million shares with net proceeds of about $65.5 million** The offering extends the company's cash runway through the end of 2026** In the last 12 months, AMLX has fallen 84%   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN13H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AMLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"AMLX","fiscalQuarterEnding":"2025/03","expectedEps":-0.45,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.42},{"market":"US","date":"2025-03-04","symbol":"AMLX","fiscalQuarterEnding":"2024/12","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741064400000,"reportTimeType":"pre","actualEps":-0.55},{"market":"US","date":"2024-11-07","symbol":"AMLX","fiscalQuarterEnding":"2024/09","expectedEps":-0.47,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-08-08","symbol":"AMLX","fiscalQuarterEnding":"2024/06","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-0.73},{"market":"US","date":"2024-05-09","symbol":"AMLX","fiscalQuarterEnding":"2024/03","expectedEps":0.24,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AMLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AMLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.4286,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4286,"analysts":7,"updateTime":1748664000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AMLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AMLX","date":"2025-06-13","current":-2.248312,"percent":0.554893,"low":-27.24786,"twenty":-13.28689,"median":-7.071912,"eighty":-0.925203,"high":660.566108,"avg":37.681835,"sd":151.561676,"marketCap":492058800},"quantilePoints":[{"date":"2022-01-07","current":-14.965618,"twenty":-15.735846,"median":-15.735846,"eighty":-15.273709,"marketCap":1020340854},{"date":"2022-01-14","current":-17.069252,"twenty":-16.953304,"median":-16.183076,"eighty":-15.273709,"marketCap":1163764527},{"date":"2022-01-21","current":-15.338309,"twenty":-17.016247,"median":-16.328011,"eighty":-15.417816,"marketCap":1045750560},{"date":"2022-01-28","current":-16.564048,"twenty":-16.799258,"median":-16.025717,"eighty":-15.619898,"marketCap":1129320260},{"date":"2022-02-04","current":-18.651119,"twenty":-18.372842,"median":-16.597176,"eighty":-15.696092,"marketCap":1271614612},{"date":"2022-02-11","current":-15.942897,"twenty":-17.579425,"median":-16.564048,"eighty":-15.735846,"marketCap":1086970750},{"date":"2022-02-18","current":-21.939082,"twenty":-18.462288,"median":-16.667574,"eighty":-15.754066,"marketCap":1495784684},{"date":"2022-02-25","current":-25.657711,"twenty":-19.073502,"median":-16.791804,"eighty":-15.826948,"marketCap":1749317082},{"date":"2022-03-04","current":-22.684464,"twenty":-21.939082,"median":-17.052688,"eighty":-15.942897,"marketCap":1546604096},{"date":"2022-03-11","current":-21.541545,"twenty":-22.684464,"median":-17.512341,"eighty":-16.025717,"marketCap":1468680998},{"date":"2022-03-18","current":-18.841605,"twenty":-22.361465,"median":-18.560016,"eighty":-16.24105,"marketCap":1284601795},{"date":"2022-03-25","current":-20.705061,"twenty":-21.939082,"median":-18.237018,"eighty":-16.28246,"marketCap":1411650325},{"date":"2022-04-01","current":-8.475859,"twenty":-21.905954,"median":-17.624148,"eighty":-15.826948,"marketCap":745290715},{"date":"2022-04-08","current":-8.982567,"twenty":-21.541545,"median":-17.06097,"eighty":-15.603334,"marketCap":789846138},{"date":"2022-04-14","current":-7.771731,"twenty":-21.528294,"median":-16.965727,"eighty":-13.72994,"marketCap":683376036},{"date":"2022-04-22","current":-6.560894,"twenty":-20.869045,"median":-16.804227,"eighty":-9.310283,"marketCap":576905934},{"date":"2022-04-29","current":-5.922572,"twenty":-20.605676,"median":-16.667574,"eighty":-8.660117,"marketCap":520777674},{"date":"2022-05-06","current":-5.034186,"twenty":-19.593613,"median":-16.564048,"eighty":-7.877021,"marketCap":442661022},{"date":"2022-05-13","current":-4.079021,"twenty":-19.267301,"median":-16.261755,"eighty":-7.076815,"marketCap":494605759},{"date":"2022-05-20","current":-4.199702,"twenty":-19.20767,"median":-15.942897,"eighty":-6.639861,"marketCap":509239066},{"date":"2022-05-27","current":-4.23832,"twenty":-19.098348,"median":-15.735846,"eighty":-6.288455,"marketCap":513921724},{"date":"2022-06-03","current":-5.961646,"twenty":-19.02381,"median":-15.644744,"eighty":-5.98953,"marketCap":722885341},{"date":"2022-06-10","current":-6.531261,"twenty":-18.965835,"median":-14.965618,"eighty":-5.946016,"marketCap":791954547},{"date":"2022-06-17","current":-8.606975,"twenty":-18.884671,"median":-12.812292,"eighty":-5.98953,"marketCap":1043647419},{"date":"2022-06-24","current":-9.031773,"twenty":-18.838292,"median":-9.572716,"eighty":-6.047604,"marketCap":1095156658},{"date":"2022-07-01","current":-9.398643,"twenty":-18.760441,"median":-9.500016,"eighty":-6.16474,"marketCap":1139641910},{"date":"2022-07-08","current":-10.721308,"twenty":-18.632898,"median":-9.557942,"eighty":-6.256367,"marketCap":1300022949},{"date":"2022-07-15","current":-9.89585,"twenty":-18.528544,"median":-9.681037,"eighty":-6.279867,"marketCap":1199931133},{"date":"2022-07-22","current":-10.644072,"twenty":-18.336402,"median":-9.891022,"eighty":-6.326623,"marketCap":1290657633},{"date":"2022-07-29","current":-13.028731,"twenty":-18.053157,"median":-10.004462,"eighty":-6.460206,"marketCap":1579811769},{"date":"2022-08-05","current":-12.029491,"twenty":-17.90905,"median":-10.243411,"eighty":-6.531923,"marketCap":1458647991},{"date":"2022-08-12","current":-9.562145,"twenty":-17.579425,"median":-10.400296,"eighty":-6.536805,"marketCap":1466842643},{"date":"2022-08-19","current":-9.485831,"twenty":-17.334277,"median":-10.06963,"eighty":-6.548772,"marketCap":1455135998},{"date":"2022-08-26","current":-10.039108,"twenty":-17.065939,"median":-9.989202,"eighty":-6.580636,"marketCap":1540009176},{"date":"2022-09-02","current":-6.898786,"twenty":-17.03778,"median":-9.89585,"eighty":-6.660919,"marketCap":1058280726},{"date":"2022-09-09","current":-11.401313,"twenty":-16.97815,"median":-9.89585,"eighty":-6.659603,"marketCap":1748972792},{"date":"2022-09-16","current":-11.210528,"twenty":-16.953304,"median":-9.989202,"eighty":-6.666184,"marketCap":1719706179},{"date":"2022-09-23","current":-10.634357,"twenty":-16.878765,"median":-10.096343,"eighty":-6.830104,"marketCap":1631321008},{"date":"2022-09-30","current":-10.741197,"twenty":-16.804227,"median":-10.278624,"eighty":-6.898786,"marketCap":1647710311},{"date":"2022-10-07","current":-13.802176,"twenty":-16.779381,"median":-10.619936,"eighty":-6.916248,"marketCap":2117267640},{"date":"2022-10-14","current":-14.91268,"twenty":-16.704843,"median":-10.68269,"eighty":-6.955732,"marketCap":2287620052},{"date":"2022-10-21","current":-15.663927,"twenty":-16.630305,"median":-10.741197,"eighty":-7.071912,"marketCap":2402862058},{"date":"2022-10-28","current":-15.698467,"twenty":-16.564048,"median":-10.820266,"eighty":-7.107086,"marketCap":2408160541},{"date":"2022-11-04","current":-14.839283,"twenty":-16.564048,"median":-11.050268,"eighty":-7.166312,"marketCap":2276360776},{"date":"2022-11-11","current":-12.241999,"twenty":-16.414972,"median":-11.147569,"eighty":-7.617391,"marketCap":2252711412},{"date":"2022-11-18","current":-12.598457,"twenty":-16.350411,"median":-11.290658,"eighty":-7.771731,"marketCap":2318305067},{"date":"2022-11-25","current":-13.952278,"twenty":-16.29605,"median":-11.35934,"eighty":-7.771731,"marketCap":2567428447},{"date":"2022-12-02","current":-14.125106,"twenty":-16.249332,"median":-11.460456,"eighty":-7.806593,"marketCap":2599231432},{"date":"2022-12-09","current":-12.836096,"twenty":-16.1662,"median":-11.775251,"eighty":-7.885736,"marketCap":2362034171},{"date":"2022-12-16","current":-12.843297,"twenty":-16.050071,"median":-11.935471,"eighty":-8.033728,"marketCap":2363359296},{"date":"2022-12-23","current":-12.803691,"twenty":-15.960795,"median":-12.029491,"eighty":-8.236016,"marketCap":2356071112},{"date":"2022-12-30","current":-13.304172,"twenty":-15.943564,"median":-12.241999,"eighty":-8.385046,"marketCap":2448167255},{"date":"2023-01-06","current":-13.318575,"twenty":-15.896517,"median":-12.362571,"eighty":-8.462395,"marketCap":2450817503},{"date":"2023-01-13","current":-13.498604,"twenty":-15.790507,"median":-12.391845,"eighty":-8.473431,"marketCap":2483945612},{"date":"2023-01-20","current":-13.275368,"twenty":-15.735846,"median":-12.443631,"eighty":-8.502082,"marketCap":2442866757},{"date":"2023-01-27","current":-14.737206,"twenty":-15.72837,"median":-12.465235,"eighty":-8.626816,"marketCap":2711867002},{"date":"2023-02-03","current":-13.192554,"twenty":-15.696004,"median":-12.546391,"eighty":-8.713372,"marketCap":2427627827},{"date":"2023-02-10","current":-12.278005,"twenty":-15.681709,"median":-12.523129,"eighty":-8.748896,"marketCap":2259337033},{"date":"2023-02-17","current":-13.368983,"twenty":-15.658746,"median":-12.575053,"eighty":-8.817175,"marketCap":2460093374},{"date":"2023-02-24","current":-12.425629,"twenty":-15.638022,"median":-12.582254,"eighty":-8.982159,"marketCap":2286502083},{"date":"2023-03-03","current":-12.321212,"twenty":-15.603334,"median":-12.537247,"eighty":-8.982567,"marketCap":2267287779},{"date":"2023-03-10","current":-11.039402,"twenty":-15.534402,"median":-12.530188,"eighty":-9.031773,"marketCap":2031415643},{"date":"2023-03-17","current":-10.186966,"twenty":-15.504179,"median":-12.49404,"eighty":-9.054954,"marketCap":2020839392},{"date":"2023-03-24","current":-9.665679,"twenty":-15.486909,"median":-12.456774,"eighty":-9.147083,"marketCap":1917428991},{"date":"2023-03-31","current":-9.867467,"twenty":-15.435099,"median":-12.43283,"eighty":-9.169128,"marketCap":1957458823},{"date":"2023-04-06","current":-9.352906,"twenty":-15.421283,"median":-12.415671,"eighty":-9.271642,"marketCap":1855382750},{"date":"2023-04-14","current":-10.284497,"twenty":-15.404013,"median":-12.363817,"eighty":-9.314874,"marketCap":2040187145},{"date":"2023-04-21","current":-10.371939,"twenty":-15.352203,"median":-12.317611,"eighty":-9.344721,"marketCap":2057533405},{"date":"2023-04-28","current":-9.540583,"twenty":-15.33867,"median":-12.281606,"eighty":-9.352541,"marketCap":1892613220},{"date":"2023-05-05","current":-9.381574,"twenty":-15.156691,"median":-12.115978,"eighty":-9.37584,"marketCap":1861069667},{"date":"2023-05-12","current":-12.985377,"twenty":-14.994752,"median":-12.108777,"eighty":-9.395229,"marketCap":1934223866},{"date":"2023-05-19","current":-12.108956,"twenty":-14.947446,"median":-12.115978,"eighty":-9.401237,"marketCap":1803677398},{"date":"2023-05-26","current":-11.860914,"twenty":-14.918725,"median":-12.116976,"eighty":-9.404582,"marketCap":1766730562},{"date":"2023-06-02","current":-11.026591,"twenty":-14.881594,"median":-12.108866,"eighty":-9.409977,"marketCap":1642454838},{"date":"2023-06-09","current":-11.838365,"twenty":-14.847918,"median":-12.041308,"eighty":-9.445302,"marketCap":1763371758},{"date":"2023-06-16","current":-11.166396,"twenty":-14.778037,"median":-12.006124,"eighty":-9.4782,"marketCap":1663279418},{"date":"2023-06-23","current":-11.175416,"twenty":-14.689959,"median":-11.960384,"eighty":-9.490139,"marketCap":1664622940},{"date":"2023-06-30","current":-9.461672,"twenty":-14.615348,"median":-11.875318,"eighty":-9.487985,"marketCap":1409353885},{"date":"2023-07-07","current":-9.276768,"twenty":-14.600384,"median":-11.818255,"eighty":-9.461672,"marketCap":1381811698},{"date":"2023-07-14","current":-10.372662,"twenty":-14.560777,"median":-11.775251,"eighty":-9.461672,"marketCap":1545049541},{"date":"2023-07-21","current":-10.106581,"twenty":-14.525026,"median":-11.523392,"eighty":-9.466753,"marketCap":1505415661},{"date":"2023-07-28","current":-10.038933,"twenty":-14.511152,"median":-11.468324,"eighty":-9.484221,"marketCap":1495339251},{"date":"2023-08-04","current":-10.169719,"twenty":-14.445559,"median":-11.399203,"eighty":-9.485831,"marketCap":1514820310},{"date":"2023-08-11","current":-19.589727,"twenty":-14.445559,"median":-11.396399,"eighty":-9.496602,"marketCap":1426386819},{"date":"2023-08-18","current":-18.701388,"twenty":-14.600384,"median":-11.401111,"eighty":-9.500016,"marketCap":1361704186},{"date":"2023-08-25","current":-20.107925,"twenty":-14.86087,"median":-11.504635,"eighty":-9.535435,"marketCap":1464118355},{"date":"2023-09-01","current":-19.950615,"twenty":-15.111286,"median":-11.536747,"eighty":-9.540583,"marketCap":1452664139},{"date":"2023-09-08","current":-19.321375,"twenty":-15.404013,"median":-11.782004,"eighty":-9.55447,"marketCap":1406847273},{"date":"2023-09-15","current":-18.146176,"twenty":-15.510224,"median":-11.838365,"eighty":-9.561304,"marketCap":1321277540},{"date":"2023-09-22","current":-16.730386,"twenty":-15.668372,"median":-11.914636,"eighty":-9.580399,"marketCap":1218189593},{"date":"2023-09-29","current":-17.119034,"twenty":-15.754066,"median":-11.982756,"eighty":-9.586985,"marketCap":1246488245},{"date":"2023-10-06","current":-16.443526,"twenty":-16.050071,"median":-12.0354,"eighty":-9.604096,"marketCap":1197302493},{"date":"2023-10-13","current":-16.29547,"twenty":-16.249332,"median":-12.108777,"eighty":-9.611049,"marketCap":1186522054},{"date":"2023-10-20","current":-15.314596,"twenty":-16.285062,"median":-12.116976,"eighty":-9.618907,"marketCap":1115101646},{"date":"2023-10-27","current":-14.759384,"twenty":-16.274178,"median":-12.163074,"eighty":-9.620949,"marketCap":1074675000},{"date":"2023-11-03","current":-16.674865,"twenty":-16.274178,"median":-12.257781,"eighty":-9.623732,"marketCap":1214146928},{"date":"2023-11-10","current":450.85384,"twenty":-16.339423,"median":-12.267893,"eighty":-9.620949,"marketCap":827767651},{"date":"2023-11-17","current":446.073172,"twenty":-16.292868,"median":-12.208173,"eighty":-9.585468,"marketCap":818990343},{"date":"2023-11-24","current":484.318522,"twenty":-16.28246,"median":-12.115978,"eighty":-9.540583,"marketCap":889208807},{"date":"2023-12-01","current":520.725154,"twenty":-16.24105,"median":-12.108777,"eighty":-9.485831,"marketCap":956051382},{"date":"2023-12-08","current":522.931616,"twenty":-16.175174,"median":-12.029491,"eighty":-9.457162,"marketCap":960102447},{"date":"2023-12-15","current":542.054291,"twenty":-16.147488,"median":-11.981987,"eighty":-9.401886,"marketCap":995211679},{"date":"2023-12-22","current":513.002535,"twenty":-16.036371,"median":-11.889723,"eighty":-9.351083,"marketCap":941872654},{"date":"2023-12-29","current":542.422035,"twenty":-16.030819,"median":-11.849639,"eighty":-9.28907,"marketCap":995886856},{"date":"2024-01-05","current":611.925604,"twenty":-16.026838,"median":-11.798146,"eighty":-9.172617,"marketCap":1123495409},{"date":"2024-01-12","current":596.480367,"twenty":-16.009487,"median":-11.66078,"eighty":-8.992408,"marketCap":1095137953},{"date":"2024-01-19","current":547.202704,"twenty":-15.944565,"median":-11.523392,"eighty":-8.742138,"marketCap":1004664164},{"date":"2024-01-26","current":565.222148,"twenty":-15.942897,"median":-11.468324,"eighty":-8.471813,"marketCap":1037747863},{"date":"2024-02-02","current":609.351398,"twenty":-15.826948,"median":-11.399203,"eighty":-7.903343,"marketCap":1118769167},{"date":"2024-02-09","current":568.531842,"twenty":-15.82354,"median":-11.35934,"eighty":-7.617391,"marketCap":1043824461},{"date":"2024-02-16","current":565.589892,"twenty":-15.749512,"median":-11.333465,"eighty":-6.955732,"marketCap":1038423041},{"date":"2024-02-23","current":25.505487,"twenty":-15.738579,"median":-11.295413,"eighty":-6.79732,"marketCap":1256680857},{"date":"2024-03-01","current":25.931954,"twenty":-15.735846,"median":-11.210528,"eighty":-6.545379,"marketCap":1277693320},{"date":"2024-03-08","current":26.097038,"twenty":-15.705943,"median":-11.186691,"eighty":-6.413487,"marketCap":1285827176},{"date":"2024-03-15","current":4.360971,"twenty":-15.688617,"median":-11.153292,"eighty":-6.087088,"marketCap":214869380},{"date":"2024-03-22","current":3.94826,"twenty":-15.668372,"median":-11.128797,"eighty":-5.859309,"marketCap":194534738},{"date":"2024-03-28","current":3.962017,"twenty":-15.648384,"median":-11.044835,"eighty":-4.906998,"marketCap":195212560},{"date":"2024-04-05","current":3.590578,"twenty":-15.617209,"median":-11.017571,"eighty":-4.329072,"marketCap":176911382},{"date":"2024-04-12","current":3.150354,"twenty":-15.591102,"median":-10.839424,"eighty":-4.211287,"marketCap":155221098},{"date":"2024-04-19","current":2.723887,"twenty":-15.55382,"median":-10.788969,"eighty":-4.079021,"marketCap":134208635},{"date":"2024-04-26","current":2.456825,"twenty":-15.516268,"median":-10.74692,"eighty":-3.715047,"marketCap":121050233},{"date":"2024-05-03","current":2.760478,"twenty":-15.493817,"median":-10.721308,"eighty":2.527963,"marketCap":136011498},{"date":"2024-05-10","current":-1.807875,"twenty":-15.455823,"median":-10.639214,"eighty":2.639017,"marketCap":128530865},{"date":"2024-05-17","current":-1.750482,"twenty":-15.424737,"median":-10.575606,"eighty":2.605891,"marketCap":124450520},{"date":"2024-05-24","current":-1.702655,"twenty":-15.407467,"median":-10.55061,"eighty":2.581476,"marketCap":121050233},{"date":"2024-05-31","current":-1.607,"twenty":-15.376381,"median":-10.462744,"eighty":2.542829,"marketCap":114249658},{"date":"2024-06-07","current":-1.683524,"twenty":-15.339392,"median":-10.375302,"eighty":2.481669,"marketCap":119690118},{"date":"2024-06-14","current":-1.607,"twenty":-15.333566,"median":-10.371939,"eighty":2.451304,"marketCap":114249658},{"date":"2024-06-21","current":-1.578303,"twenty":-15.314596,"median":-10.345603,"eighty":2.42922,"marketCap":112209485},{"date":"2024-06-28","current":-1.846137,"twenty":-15.233272,"median":-10.336583,"eighty":0.837689,"marketCap":131251095},{"date":"2024-07-05","current":-1.693089,"twenty":-15.107531,"median":-10.295995,"eighty":-1.553433,"marketCap":120370175},{"date":"2024-07-12","current":-2.180928,"twenty":-15.067132,"median":-10.277956,"eighty":-1.570651,"marketCap":155053107},{"date":"2024-07-15","current":-2.066143,"twenty":-15.041754,"median":-10.273446,"eighty":-1.572564,"marketCap":146892417},{"date":"2024-08-02","current":-1.980053,"twenty":-15.016375,"median":-10.2672,"eighty":-1.574477,"marketCap":140771900},{"date":"2024-08-09","current":-0.738827,"twenty":-14.951989,"median":-10.237413,"eighty":-1.574477,"marketCap":122548442},{"date":"2024-08-16","current":-0.886592,"twenty":-14.924769,"median":-10.186966,"eighty":-0.851292,"marketCap":147058130},{"date":"2024-08-23","current":-0.91122,"twenty":-14.881594,"median":-10.176877,"eighty":-0.87551,"marketCap":151143078},{"date":"2024-08-30","current":-0.870174,"twenty":-14.847918,"median":-10.167464,"eighty":-0.872636,"marketCap":144334832},{"date":"2024-09-06","current":-0.90301,"twenty":-14.807323,"median":-10.14717,"eighty":-0.871816,"marketCap":149781429},{"date":"2024-09-13","current":-1.022044,"twenty":-14.750513,"median":-10.111091,"eighty":-0.874278,"marketCap":169525345},{"date":"2024-09-20","current":-1.182123,"twenty":-14.689959,"median":-10.097576,"eighty":-0.875099,"marketCap":196077507},{"date":"2024-09-27","current":-1.31347,"twenty":-14.611607,"median":-10.070502,"eighty":-0.880435,"marketCap":217863897},{"date":"2024-10-04","current":-1.20675,"twenty":-14.591806,"median":-10.05255,"eighty":-0.886592,"marketCap":200162455},{"date":"2024-10-11","current":-1.420189,"twenty":-14.573388,"median":-9.984815,"eighty":-0.893159,"marketCap":235565339},{"date":"2024-10-18","current":-1.609,"twenty":-14.563346,"median":-9.930486,"eighty":-0.90301,"marketCap":266883274},{"date":"2024-10-25","current":-2.01125,"twenty":-14.546477,"median":-9.907825,"eighty":-0.904652,"marketCap":333604093},{"date":"2024-10-31","current":-2.16312,"twenty":-14.522251,"median":-9.891022,"eighty":-0.907936,"marketCap":358794606},{"date":"2024-11-08","current":-1.71606,"twenty":-14.498033,"median":-9.867467,"eighty":-0.91122,"marketCap":445259340},{"date":"2024-11-15","current":-1.317221,"twenty":-14.412048,"median":-9.847288,"eighty":-0.912041,"marketCap":341773989},{"date":"2024-11-22","current":-1.361828,"twenty":-14.258948,"median":-9.820895,"eighty":-0.917787,"marketCap":353348008},{"date":"2024-11-29","current":-1.453666,"twenty":-14.182716,"median":-9.792708,"eighty":-0.927638,"marketCap":377176872},{"date":"2024-12-06","current":-1.304101,"twenty":-14.161433,"median":-9.786381,"eighty":-0.927638,"marketCap":338369865},{"date":"2024-12-13","current":-1.15716,"twenty":-14.135908,"median":-9.753975,"eighty":-0.972788,"marketCap":300243683},{"date":"2024-12-20","current":-1.039082,"twenty":-14.125106,"median":-9.730036,"eighty":-1.022044,"marketCap":269606573},{"date":"2024-12-27","current":-1.067946,"twenty":-14.113584,"median":-9.665679,"eighty":-1.031477,"marketCap":277095644},{"date":"2025-01-03","current":-1.025963,"twenty":-14.015648,"median":-9.642275,"eighty":-1.012318,"marketCap":266202449},{"date":"2025-01-10","current":-0.989228,"twenty":-13.942196,"median":-9.632047,"eighty":-1.007595,"marketCap":256670904},{"date":"2025-01-17","current":-0.918381,"twenty":-13.90403,"median":-9.621327,"eighty":-0.945698,"marketCap":238288638},{"date":"2025-01-24","current":-0.934125,"twenty":-13.865081,"median":-9.609998,"eighty":-0.927638,"marketCap":242373586},{"date":"2025-01-31","current":-0.921005,"twenty":-13.841127,"median":-9.584963,"eighty":-0.918381,"marketCap":238969462},{"date":"2025-02-07","current":-0.98398,"twenty":-13.8128,"median":-9.549263,"eighty":-0.918381,"marketCap":255309255},{"date":"2025-02-14","current":-0.941996,"twenty":-13.770986,"median":-9.500016,"eighty":-0.918381,"marketCap":244416060},{"date":"2025-02-21","current":-0.923629,"twenty":-13.646228,"median":-9.485831,"eighty":-0.918381,"marketCap":239650287},{"date":"2025-02-28","current":-0.829167,"twenty":-13.53821,"median":-9.464213,"eighty":-0.913133,"marketCap":215140598},{"date":"2025-03-07","current":-0.814527,"twenty":-13.520208,"median":-9.457162,"eighty":-0.907115,"marketCap":245777709},{"date":"2025-03-14","current":-1.077642,"twenty":-13.509406,"median":-9.403571,"eighty":-0.905261,"marketCap":325171057},{"date":"2025-03-21","current":-1.095261,"twenty":-13.498604,"median":-9.381574,"eighty":-0.907115,"marketCap":330487205},{"date":"2025-03-28","current":-1.13637,"twenty":-13.4734,"median":-9.335179,"eighty":-0.907885,"marketCap":342891551},{"date":"2025-04-04","current":-1.030661,"twenty":-13.401388,"median":-9.276768,"eighty":-0.91122,"marketCap":310994662},{"date":"2025-04-11","current":-1.024788,"twenty":-13.390586,"median":-9.158106,"eighty":-0.91122,"marketCap":309222613},{"date":"2025-04-17","current":-1.121688,"twenty":-13.373304,"median":-9.043363,"eighty":-0.91275,"marketCap":338461427},{"date":"2025-04-25","current":-1.53865,"twenty":-13.343059,"median":-8.982159,"eighty":-0.914886,"marketCap":464276932},{"date":"2025-05-02","current":-1.509287,"twenty":-13.325056,"median":-8.72416,"eighty":-0.91567,"marketCap":455416685},{"date":"2025-05-09","current":-1.854176,"twenty":-13.322175,"median":-8.475859,"eighty":-0.917856,"marketCap":405799303},{"date":"2025-05-16","current":-1.841009,"twenty":-13.322175,"median":-8.367278,"eighty":-0.918381,"marketCap":402917713},{"date":"2025-05-23","current":-2.183143,"twenty":-13.319295,"median":-7.903343,"eighty":-0.92048,"marketCap":477796226},{"date":"2025-05-30","current":-1.995784,"twenty":-13.314254,"median":-7.771731,"eighty":-0.922579,"marketCap":436791326},{"date":"2025-06-06","current":-2.05688,"twenty":-13.307052,"median":-7.391851,"eighty":-0.923629,"marketCap":450162489},{"date":"2025-06-13","current":-2.248312,"twenty":-13.28689,"median":-7.071912,"eighty":-0.925203,"marketCap":492058800}],"updateTime":1749902134055}}}